← Eichor
Study identifier: NCT06235229 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

A Study of GC012F in Patients With Relapsed/Refractory Multiple Myeloma

Condition: Multiple Myeloma  ·  Sponsor: Gracell Biotechnologies (Shanghai) Co., Ltd.

PhasePhase 1/Phase 2
Planned participants110
Who can joinAll sexes, 18 Years to 75 Years
Healthy volunteersNo

About this study

This study is a single-arm, open-lable, phase I/II study to evaluate the efficacy and safety of GC012F in subjects with relapsed/refractory multiple myeloma.

This description comes directly from the study's public registry record.

Talk to the study team

He Huang, MD  ·  0571-88208277  ·  hehuangyu@126.com

Juan Du, MD  ·  021-81885423  ·  juan_du@live.com

Always discuss trial participation with your own doctor first.

Locations (10)

Research SiteBeijing, ChinaActive Not Recruiting
Research SiteBeijing, ChinaRecruiting
Research SiteHangzhou, ChinaRecruiting
Research SiteJinan, ChinaRecruiting
Research SiteShanghai, ChinaRecruiting
Research SiteShanghai, ChinaRecruiting
Research SiteShenyang, ChinaRecruiting
Research SiteWenzhou, ChinaRecruiting
Research SiteWuhan, ChinaRecruiting
Research SiteXi'an, ChinaActive Not Recruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06235229